	US 12,186,392 B2
	Combination therapy of an anti CD20 antibody with a BTK inhibitor
Christian Klein, Bonstetten (CH); Toshio Yoshizawa, Osaka (JP); and Tomoko Yasuhiro, Osaka (JP)
Assigned to Ono Pharmaceutical Co., Ltd., Osaka (JP); and Hoffmann-La Roche Inc., Little Falls, NJ (US)
Filed by Ono Pharmaceutical Co., Ltd., Osaka (JP); and HOFFMANN-LA ROCHE INC., Little Falls, NJ (US)
Filed on Nov. 11, 2019, as Appl. No. 16/679,483.
Application 16/679,483 is a continuation of application No. 14/532,247, filed on Nov. 4, 2014, abandoned.
Claims priority of application No. 13192006 (EP), filed on Nov. 7, 2013.
Prior Publication US 2020/0171153 A1, Jun. 4, 2020
Int. Cl. A61K 39/395 (2006.01); A61K 31/522 (2006.01); A61K 39/40 (2006.01); A61K 45/06 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01); C07K 16/00 (2006.01)

CPC A61K 39/39558 (2013.01) [A61K 31/522 (2013.01); A61K 45/06 (2013.01); C07K 16/2887 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01)]

4 Claims

1. A method of treatment of a patient suffering from a B-Cell Non-Hodgkin's lymphomas or a lymphocytic leukemias, comprising the step of administering a therapeutically effective amount of rituximab in combination with a therapeutically effective amount of 6-amino-9-[(3R)-1-(2-butynoyl)-3-pyrrolidinyl]-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one or a salt thereof, to said patient in the need of such treatment.